Acta Neurologica Scandinavica 1992-08-01

Debrisoquine hydroxylation in Parkinson's disease.

M J Steiger, P Lledo, N P Quinn, C D Marsden, P Turner, P G Jenner

Index: Acta Neurol. Scand 86(2) , 159-64, (1992)

Full Text: HTML

Abstract

Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD patients compared either to other parkinsonians, or to controls. Nor was there a significant correlation between the age of disease onset and DBQ metabolic ratio (MR). The results do not support the suggestion that impairment of DBQ metabolism (and hence cytochrome P450) is a primary defect in YOPD. However, in comparison with controls, MR values were modestly but significantly higher in PD patients, even in those not treated with drugs known to affect DBQ metabolism.

Related Compounds

Related Articles:

Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.

1999-08-01

[Biochem. Pharmacol. 58(3) , 439-45, (1999)]

Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.

1998-03-01

[Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998)]

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

2005-01-01

[Clin. Chem. Lab Med. 43(3) , 275-9, (2005)]

Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.

1999-01-01

[Chirality 11(7) , 591-7, (1999)]

Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.

1993-08-01

[J. Pharm. Biomed. Anal. 11(8) , 745-9, (1993)]

More Articles...